PRPH — ProPhase Labs, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 868278 ·
Last close
$0.04
Market Cap
$560.6K
52W High
$0.15
52W Low
$0.04
ADV30
103,437
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 478,000 | 167,000 | -2,605,000 | -5,354,000 | 58,730,000 | 31,000 | 59,344,000 |
| Dec 2025 | 784,000 | 247,000 | -5,726,000 | -7,398,000 | 59,871,000 | 90,000 | 56,363,000 |
| Sep 2025 | 883,000 | -123,000 | -4,764,000 | -6,839,000 | 65,702,000 | 405,000 | 58,841,000 |
| Jun 2025 | 1,247,000 | 734,000 | -3,894,000 | -4,472,000 | 42,041,000 | 169,000 | 30,605,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,711,000
Investing CF
$79,000
Financing CF
$5,575,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.03
As of
2026-07-05
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,490,000
Inventory
$70,000
Receivables
$1,543,000
ST Investments
$2,000
EBIT TTM
$-15,644,000
Pretax Income TTM
$-22,689,000
Interest Exp TTM
$7,045,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,392,000
EBITDA
$-12,677,000
Free Cash Flow
$47,496,752
Enterprise Value
$9,465,429
Total Cash
$31,000
Total Debt
$8,911,000
Shares Out
14,016,204
Trailing EPS
$-1.85
Book Value
$-0.04
ROE
-331.8%
ROA
-19.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,345,000 | -18,047,000 | -14,743,000 | 59,871,000 | 56,363,000 | — | -8,344,000 |
| Dec 2024 | 6,770,000 | -38,629,000 | -53,364,000 | 63,200,000 | 55,847,000 | — | -17,538,000 |
| Dec 2023 | 34,984,000 | -21,220,000 | -16,782,000 | 91,927,000 | 42,544,000 | — | -11,888,000 |
| Dec 2022 | 122,647,000 | 23,595,000 | 18,463,000 | 87,648,000 | 24,017,000 | — | 28,551,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$33,981,000
NetIncome TTM
$-10,760,000
OpCashFlow TTM
$0
Assets (Latest)
$63,200,000
Forward EPS
$0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | $646.1K | $0.39 | — |
| EMMA | Emmaus Life Sciences, Inc. | $701.9K | $0.01 | — |
| CYTOF | Altamira Therapeutics Ltd. | $445.8K | $0.08 | — |
| ZVSA | ZyVersa Therapeutics, Inc. | $817.7K | $0.10 | — |
| RGBPP | Regen BioPharma Inc | $841.2K | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
2026-04-15 13:05 · Yahoo
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
2026-03-17 12:00 · Yahoo
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
2026-02-03 12:00 · Yahoo
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
2026-02-02 13:00 · Yahoo
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
2026-01-26 12:00 · Yahoo
ProPhase Labs Uplists from Pink Sheets to OTC Market
2026-01-22 12:00 · Yahoo
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
2026-01-05 10:00 · Yahoo
BC-Most Active Stocks
2025-12-19 15:30 · Yahoo
ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger
2025-12-19 13:51 · Yahoo
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
2025-12-19 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.